

Attila Marcell Szasz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8492684/publications.pdf>

Version: 2024-02-01

52
papers

1,681
citations

516710
16
h-index

289244
40
g-index

54
all docs

54
docs citations

54
times ranked

3804
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. <i>Oncotarget</i> , 2016, 7, 49322-49333.	1.8	821
2	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. <i>Nature Communications</i> , 2017, 8, 14944.	12.8	126
3	Correlations of Differentially Expressed Gap Junction Connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with Breast Cancer Progression and Prognosis. <i>PLoS ONE</i> , 2014, 9, e112541.	2.5	74
4	Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. <i>Diagnostic Pathology</i> , 2017, 12, 20.	2.0	67
5	Expression of Tight Junction Protein Claudin-4 in Basal-Like Breast Carcinomas. <i>Pathology and Oncology Research</i> , 2009, 15, 59-64.	1.9	55
6	Quo Vadis Oncological Hyperthermia (2020)? <i>Frontiers in Oncology</i> , 2020, 10, 1690.	2.8	40
7	Clinical protein science in translational medicine targeting malignant melanoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 293-332.	5.3	33
8	Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. <i>Journal of Urology</i> , 2016, 195, 1690-1696.	0.4	32
9	The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e56707.	2.5	28
10	PD-1, PD-L1 and CTLA-4 in pregnancy-related " and in early-onset breast cancer: A comparative study. <i>Breast</i> , 2017, 35, 69-77.	2.2	27
11	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. <i>PLoS ONE</i> , 2017, 12, e0176167.	2.5	27
12	Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. <i>Journal of Clinical Pathology</i> , 2015, 68, 274-282.	2.0	21
13	Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 115-127.	1.9	20
14	The Human Melanoma Proteome Atlas" Complementing the melanoma transcriptome. <i>Clinical and Translational Medicine</i> , 2021, 11, e451.	4.0	20
15	Opposite prognostic roles of HIF1 \pm and HIF2 \pm expressions in bone metastatic clear cell renal cell cancer. <i>Oncotarget</i> , 0, 7, 42086-42098.	1.8	19
16	Transitional cell and clear cell renal carcinoma: differentiation of distinct histological types with multiphase CT. <i>Acta Radiologica</i> , 2014, 55, 1112-1119.	1.1	17
17	3-dimensional digital reconstruction of the murine coronary system for the evaluation of chronic allograft vasculopathy. <i>Diagnostic Pathology</i> , 2015, 10, 16.	2.0	17
18	Cancer heterogeneity determined by functional proteomics. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 132-142.	5.0	17

#	ARTICLE	IF	CITATIONS
19	Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 256-267.	2.5	16
20	Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?. <i>Human Pathology</i> , 2017, 65, 31-40.	2.0	16
21	The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. <i>Cancers</i> , 2019, 11, 1981.	3.7	16
22	Challenging the heterogeneity of disease presentation in malignant melanoma—impact on patient treatment. <i>Cell Biology and Toxicology</i> , 2019, 35, 1-14.	5.3	15
23	The human melanoma proteome atlas—Defining the molecular pathology. <i>Clinical and Translational Medicine</i> , 2021, 11, e473.	4.0	14
24	Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. <i>International Urology and Nephrology</i> , 2013, 45, 727-733.	1.4	13
25	Breast- and Salivary Gland-Derived Adenoid Cystic Carcinomas: Potential Post-Transcriptional Divergencies. A Pilot Study Based on miRNA Expression Profiling of Four Cases and Review of the Potential Relevance of the Findings. <i>Pathology and Oncology Research</i> , 2015, 21, 29-44.	1.9	12
26	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. <i>Scientific Reports</i> , 2019, 9, 5154.	3.3	12
27	Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study. <i>Diagnostic Cytopathology</i> , 2016, 44, 466-471.	1.0	11
28	Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology. <i>Journal of Research in Medical Sciences</i> , 2014, 19, 634-8.	0.9	10
29	BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?. <i>Pathobiology</i> , 2016, 83, 1-12.	3.8	9
30	Novel functional proteins coded by the human genome discovered in metastases of melanoma patients. <i>Cell Biology and Toxicology</i> , 2020, 36, 261-272.	5.3	9
31	Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice. <i>Cancers</i> , 2020, 12, 3872.	3.7	8
32	In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. <i>Diagnostic Pathology</i> , 2016, 11, 61.	2.0	7
33	Proteomic analysis enables distinction of early—versus advanced—stage lung adenocarcinomas. <i>Clinical and Translational Medicine</i> , 2020, 10, e106.	4.0	7
34	Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 551-562.	2.8	6
35	A biobanking turning-point in the use of formalin-fixed, paraffin tumor blocks to unveil kinase signaling in melanoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e466.	4.0	6
36	Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 81.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World Journal of Gastrointestinal Oncology, 2021, 13, 1109-1120.	2.0	4
38	Current State of ERG as Biomarker in Prostatic Adenocarcinoma. Current Cancer Drug Targets, 2015, 15, 643-651.	1.6	4
39	Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database. Cancers, 2021, 13, 6224.	3.7	4
40	Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers, 2021, 13, 6105.	3.7	3
41	Basaloid carcinoma of the pancreasâ€”clinicopathological presentation and oncogenetic snapshot of a rare entity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 237-241.	2.8	2
42	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	3.7	2
43	Deconstructing Immune Cell Infiltration in Human Colorectal Cancer: A Systematic Spatiotemporal Evaluation. Genes, 2022, 13, 589.	2.4	2
44	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942.	3.7	2
45	The Petersen prognostic index revisited in Dukes B colon cancer â€” Inter-institutional differences. Pathology Research and Practice, 2016, 212, 73-76.	2.3	1
46	A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19. Frontiers in Immunology, 2020, 11, 556335.	4.8	1
47	Matrixâ€”assisted laser desorption ionization â€” mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a nonâ€”smallâ€”cell lung cancer mouse xenograft model. Clinical and Translational Medicine, 2021, 11, e481.	4.0	1
48	Expression of HIF1a and HIF2a in bone metastatic clear cell renal cell cancer and use as prognostic markers.. Journal of Clinical Oncology, 2013, 31, e15523-e15523.	1.6	1
49	Identifying resistance biomarkers against five clinically approved tyrosine kinase inhibitors in 45 cell lines.. Journal of Clinical Oncology, 2012, 30, e21005-e21005.	1.6	0
50	Genomic alterations in matching primary tumors and metastasis in breast cancer.. Journal of Clinical Oncology, 2013, 31, 1549-1549.	1.6	0
51	Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas.. Journal of Clinical Oncology, 2015, 33, 78-78.	1.6	0
52	Longitudinal Analysis of 1Î±,25-dihydroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer. Cancers, 2022, 14, 658.	3.7	0